Agios Pharm

NASDAQ AGIO

Data sourced from

and

Download Data

Agios Pharm Current Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: -19.09%

Agios Pharm Current Ratio 1 year YoY Change (%) is -19.09% for the Trailing 12 Months (TTM) ending March 31, 2024, a 34.74% change year over year. The current ratio assesses a company's short-term liquidity and its ability to cover its current liabilities with its current assets. It is calculated by dividing current assets by current liabilities. This ratio indicates the number of times a company's current assets can cover its current liabilities. A higher current ratio suggests better liquidity and a stronger ability to meet short-term obligations. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Agios Pharm Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 15.87, a -29.25% change year over year.
Agios Pharm Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 22.43, a 66.45% change year over year.
Agios Pharm Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 13.47, a 105.24% change year over year.
Agios Pharm Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 6.56, a -14.02% change year over year.

NASDAQ: AGIO

Agios Pharm

CEO	Dr. Bruce D. Car DACVP, Ph.D.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees	383
Sector	Healthcare
Industry	Biotechnology

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends